Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Mussetti, Alberto [VerfasserIn]   i
 Kanate, Abraham S. [VerfasserIn]   i
 Wang, Tao [VerfasserIn]   i
 He, Meilun [VerfasserIn]   i
 Hamadani, Mehdi [VerfasserIn]   i
 Finel, Hervé [VerfasserIn]   i
 Boumendil, Ariane [VerfasserIn]   i
 Glass, Bertram [VerfasserIn]   i
 Castagna, Luca [VerfasserIn]   i
 Dominietto, Alida [VerfasserIn]   i
 McGuirk, Joseph [VerfasserIn]   i
 Blaise, Didier [VerfasserIn]   i
 Gülbas, Zafer [VerfasserIn]   i
 Diez-Martin, Jose [VerfasserIn]   i
 Marsh, Steven G. E. [VerfasserIn]   i
 Paczesny, Sophie [VerfasserIn]   i
 Gadalla, Shahinaz M. [VerfasserIn]   i
 Dreger, Peter [VerfasserIn]   i
 Zhang, Mei-Jie [VerfasserIn]   i
 Spellman, Stephen R. [VerfasserIn]   i
 Lee, Stephanie J. [VerfasserIn]   i
 Bolon, Yung-Tsi [VerfasserIn]   i
 Sureda, Anna [VerfasserIn]   i
Titel:Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas
Verf.angabe:Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Hervé Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gülbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda
E-Jahr:2023
Jahr:28 February 2023
Umfang:9 S.
Fussnoten:Online verfügbar 25. Dezember 2022, Artikelversion 28. Februar 2023 ; Gesehen am 11.07.2023
Titel Quelle:Enthalten in: Transplantation and cellular therapy
Ort Quelle:[Amsterdam] : Elsevier B. V., 2021
Jahr Quelle:2023
Band/Heft Quelle:29(2023), 3 vom: Feb., Seite 184.e1-184.e9
ISSN Quelle:2666-6367
Abstract:When using post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis for lymphoma patients, it is currently unknown whether a matched unrelated donor (MUD) or a haploidentical related donor is preferable if both are available. In this study we wanted to test whether using a haploidentical donor has the same results of a MUD. A total of 2140 adults (34% Center for International Blood and Marrow Transplant Research, 66% European Society for Blood and Marrow Transplantation registry) aged ≥18 years who received their first haploidentical hematopoietic cell transplantation (haplo-HCT) or MUD-HCT (8/8 match at HLA-loci A, B, C, and DRB1) for lymphoma using PTCy-based GVHD prophylaxis from 2010 to 2019 were retrospectively analyzed. The majority of both MUD and haploidentical HCTs received reduced intensity/nonmyeloablative conditioning (74% and 77%, respectively) and used a peripheral blood stem cell graft (91% and 60%, respectively) and a 3-drug GVHD prophylaxis (PTCy + calcineurin inhibitor + MMF in 54% and 90%, respectively). Haploidentical HCT has less favorable results versus MUD cohort in terms of overall mortality (hazard ratio [HR= = 1.69; 95% confidence interval [CI], 1.30-2.27; P < .001), progression-free survival (HR=1.39; 95% CI, 1.10-1.79; P = .008), nonrelapse mortality (HR = 1.93; 95% CI, 1.21-3.07; P = .006), platelet engraftment (HR = 0.69; 95% CI, 0.59-0.80; P < .001), acute grade 2-4 GVHD incidence (HR = 1.65; 95% CI, 1.28-2.14; P < .001), and chronic GVHD (HR = 1.79; 95% CI, 1.30-2.48, P < .001). No significant differences were observed in terms of relapse and neutrophil engraftment. Adjusting for propensity score yielded similar results. Whenever MUD is available in a timely manner, it should be preferred over a haploidentical donor when using PTCy-based GVHD prophylaxis for patients with lymphoma.
DOI:doi:10.1016/j.jtct.2022.11.028
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.jtct.2022.11.028
 Volltext: https://www.sciencedirect.com/science/article/pii/S2666636722018012
 DOI: https://doi.org/10.1016/j.jtct.2022.11.028
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Haploidentical donor
 Lymphoma
 Matched unrelated donor
 Post-transplant cyclophosphamide
K10plus-PPN:1852358416
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69095426   QR-Code
zum Seitenanfang